August 28th 2024
The joint venture aims to disrupt pathological lncRNA interactions with RNA-binding proteins using NextRNA’s platform.
August 15th 2024
Partnership adds supply chain efficiencies, while prioritizing patient safety.
August 13th 2024
The partnership creates an integrated solution that also tackles compliance challenges within the sector.
August 12th 2024
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.
A Data-Driven Approach to Contract Performance Monitoring and Analysis
Better use of available data can add rigor to analyzing managed-markets contracts, thereby allocating rebates / discounts more effectively
2008 Market Summary From IMS Health: US Pharma Sales Up 1.3%, the Lowest in Decades
US total reaches $291.5 billion; dispensed prescriptions up 0.9%
McKesson Jumps Into Plasma, Blood-Based Products Wholesaling
New unit will ship from La Vergne, TN specialty-care products warehouse
Armada Gathers 1,000 Attendees at its 5th Specialty Pharmacy Summit
Specialty GPO is doubling attendance year-over-year
Stem Cell Therapy: Business Models Begin to Take Shape
Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy
Independent Pharmacies Promote the Value of Their Patient Contact to the Pharma Industry
Although beset by less-than-friendly federal reimbursement policies, independent pharmacies are maintaining their viability for pharmaceutical delivery
Long-Term Drug Approval Trends Highlight the Industry's Productivity Dilemma
Higher complexity—and expense—are the reality for most drug research, says Tufts
Novartis Managed Care Report Finds Higher Barriers to Drug Access
Higher co-pays, ‘NDC block policies’ and multiple tiers add to drug benefit complexity
Examining the ROI of personalized medicine
New Deloitte study finds “profound” positive and negative ROIs for combined therapies and diagnostics based on genetics